^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    YTS101

    i
    Other names: YTS101, YT-19/20, CD19/CD20 Dual-CAR-T cells, anti-CD19/CD20 (dual) STAR-T cell therapy, S101, HXYT-001, YTS-001, HXYT001, HXYT 001, YTS001
    Associations

    News

    Trials
    Company:
    BriSTAR Immunotech
    Drug class:
    CD19-targeted CAR-T immunotherapy, CD20-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    over2years
    CD19/CD20 Dual-CAR-T in B-cell Lymphoma Patients (clinicaltrials.gov)
    P1, N=12, Completed, Hebei Yanda Ludaopei Hospital | Suspended --> Completed | Trial completion date: Dec 2022 --> Sep 2021 | Trial primary completion date: Oct 2022 --> May 2021
    Trial completion • Trial completion date • Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD19 (CD19 Molecule)
    |
    CD20 positive • CD19 expression
    |
    cyclophosphamide • YTS101
    over2years
    CD19/CD20 Dual-CAR-T in B-cell Leukemia Patients (clinicaltrials.gov)
    P1, N=12, Completed, Hebei Yanda Ludaopei Hospital | Suspended --> Completed | Trial completion date: Dec 2022 --> Feb 2022 | Trial primary completion date: Oct 2022 --> Oct 2021
    Trial completion • Trial completion date • Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD19 (CD19 Molecule)
    |
    CD20 positive • CD19 expression
    |
    cyclophosphamide • YTS101
    almost3years
    CD19/CD20 Dual-CAR-T in B-cell Lymphoma Patients (clinicaltrials.gov)
    P1, N=12, Suspended, Hebei Yanda Ludaopei Hospital | Trial completion date: Nov 2021 --> Dec 2022 | Recruiting --> Suspended | Trial primary completion date: Aug 2021 --> Oct 2022
    Trial completion date • Trial suspension • Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD19 (CD19 Molecule)
    |
    CD20 positive • CD19 expression
    |
    YTS101
    almost3years
    CD19/CD20 Dual-CAR-T in B-cell Leukemia Patients (clinicaltrials.gov)
    P1, N=12, Suspended, Hebei Yanda Ludaopei Hospital | Trial completion date: Nov 2021 --> Dec 2022 | Recruiting --> Suspended | Trial primary completion date: Aug 2021 --> Oct 2022
    Trial completion date • Trial suspension • Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD19 (CD19 Molecule)
    |
    CD20 positive • CD19 expression
    |
    YTS101
    almost3years
    CD19/CD20 Dual-CAR-T in B-cell Non-Hodgkin's Lymphoma Patients. (clinicaltrials.gov)
    P1, N=12, Suspended, Beijing Tsinghua Chang Gung Hospital | Not yet recruiting --> Suspended
    Trial suspension • CAR T-Cell Therapy
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD19 (CD19 Molecule)
    |
    CD20 positive • CD19 expression
    |
    YTS101
    almost4years
    CD19/CD20 Dual-CAR-T in B-cell Non-Hodgkin's Lymphoma Patients. (clinicaltrials.gov)
    P1, N=12, Not yet recruiting, Beijing Tsinghua Chang Gung Hospital
    Clinical • New P1 trial • CAR T-Cell Therapy
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD19 (CD19 Molecule)
    |
    CD20 positive • CD19 expression
    |
    YTS101
    over4years
    CD19/CD20 Dual-CAR-T in B-cell Lymphoma Patients (clinicaltrials.gov)
    P1; Not yet recruiting --> Recruiting
    Enrollment open • Clinical
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD19 (CD19 Molecule)
    |
    CD20 positive • CD19 expression
    |
    fludarabine IV • YTS101
    over4years
    CD19/CD20 Dual-CAR-T in B-cell Leukemia Patients (clinicaltrials.gov)
    P1;Not yet recruiting --> Recruiting
    Enrollment open • Clinical
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD19 (CD19 Molecule)
    |
    CD20 positive • CD19 expression
    |
    YTS101